Black Rock Inc. Gamida Cell Ltd. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Gamida Cell Ltd. stock. As of the latest transaction made, Black Rock Inc. holds 287,565 shares of GMDA stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

287,565

Previous 289,262 0.59%

Holding current value

Previous $118,000 90.68%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.04 - $0.46 $67 - $780	-1,697 Reduced 0.59%	287,565 $11,000
Q4 2023 Feb 13, 2024	BUY	$0.25 - $1.02 $17,096 - $69,754	68,387 Added 30.96%	289,262 $118,000
Q3 2023 Nov 13, 2023	BUY	$0.85 - $1.87 $23,077 - $50,770	27,150 Added 14.01%	220,875 $227,000
Q2 2023 Aug 11, 2023	BUY	$0.73 - $2.37 $30,160 - $97,918	41,316 Added 27.11%	193,725 $373,000
Q1 2023 May 12, 2023	BUY	$0.68 - $1.71 $16,689 - $41,968	24,543 Added 19.19%	152,409 $123,000

Q4 2022 Feb 13, 2023	SELL	$1.15 - $2.1 $381,589 - $696,815	-331,817 Reduced 72.18%	127,866 $164,000
Q3 2022 Nov 14, 2022	BUY	$1.53 - $3.39 $15,440 - $34,211	10,092 Added 2.24%	459,683 $731,000
Q2 2022 Aug 12, 2022	BUY	$1.73 - $4.29 $170,789 - $423,517	98,722 Added 28.14%	449,591 $797,000
Q1 2022 May 12, 2022	SELL	$2.22 - $4.47 $28,899 - $58,190	-13,018 Reduced 3.58%	350,869 $1.46 Million
Q4 2021 Feb 10, 2022	BUY	$2.2 - $4.46 $4,681 - $9,490	2,128 Added 0.59%	363,887 $924,000
Q3 2021 Nov 09, 2021	BUY	$3.85 - $6.44 $60,679 - $101,500	15,761 Added 4.56%	361,759 $1.42 Million
Q2 2021 Aug 11, 2021	BUY	$5.85 - $8.33 $2.02 Million - $2.88 Million	345,998 New	345,998 $2.22 Million

Others Institutions Holding GMDA

# of Institutions

Shares Held

11.4M

Call Options Held

235K

Put Options Held

70.5K

View Full List

About Gamida Cell Ltd.

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

More about GMDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account